3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
72
Phase NA
41
Phase 1
26
Phase 1/2
22
Phase 3
21
Phase EARLY_PHASE1
6
Phase 2/3
2
Status
Unknown
2
Sponsor Class
OTHER
2
Study Type
Interventional
2
Sponsor
Cancer Type
Gastrointestinal
5
Genitourinary
4
Thoracic
2
Breast
2
Conditions
Prostatic Neoplasms
1
NSCLC
1
Carcinoma, Non-Small-Cell Lung
1
Breast Neoplasms
1
Interventions
Pemetrexed
23
Carboplatin
21
Cisplatin
20
pembrolizumab
15
Docetaxel
14
Paclitaxel
10
Gemcitabine
8
Drug Therapy
7
Bevacizumab
7
Gefitinib
5
Radiotherapy
4
Magnetic Resonance Spectroscopy
4
Erlotinib Hydrochloride
4
130-nm albumin-bound paclitaxel
4
cemiplimab
3
atezolizumab
3
anlotinib
3
Dexamethasone
3
dexamethasone acetate
2
dexamethasone 21-phosphate
2
cobimetinib
2
auricularum
2
aumolertinib
2
apatinib
2
Vemurafenib
2
Topotecan
2
Temozolomide
2
Surgical Procedures, Operative
2
Standard of Care
2
Specimen Handling
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Phase 2/3
×
Radiosurgery
×
Thoracic
×
Clear all
NCT03256981
2023-12-26
HALT
Institute of Cancer Research, United Kingdom
Phase 2/3
Unknown
113 enrolled
NCT02759783
2019-08-21
CORE
Royal Marsden NHS Foundation Trust
Phase 2/3
Unknown
245 enrolled